Ukusebenzisa i-Gaviscon yokuCoca

Indlela i-Antacid ikhusela ngayo kwi-Acidx ye-acid

I-Gaviscon yinto engaphezulu kwe-counter-the-counter (i-OTC) engahambelaniyo kunye nezithako ezenza umqobo wesikhubekiso okhusela umxube we-esophagus nesisu. Funda indlela isebenza ngayo ukukhusela okanye ukukhupha isifo sokuguquka kwezinto kunye neyiphi inqobo omele uyenze nale meyeza.

Sibanzi

Ukongeza kwiimveliso ezithintekayo ze-asidi ezitholakala kwiintlobo ezininzi ze-antacids (i-aluminium hydroxide kunye ne-magnesium carbonate), i-Gaviscon iqukethe i-alginic acid kunye ne-sodium bicarbonate.

Ukuhlanganiswa kwe-asidi ye-alginic kunye ne-bicarbonate kudala umqobo wentlambo ohambayo kwisisu se-asidi. Esi sikhophelo se-gel siphosa ipokethi ye-asidi ekhoyo kumbuthano wesisu kunye nesisu kwaye inokukunceda ukunciphisa inani leziqephu ze-reflux. Ikwabonelela kwakhona isenzo eside esingapheliyo ekuchaseni intliziyo kubantu abane- reflux ye-gastroesophageal disease (GERD) .

Izinzuzo

Ucwaningo oluninzi lufumene ukuba i-Gaviscon inokunciphisa impawu yokuguquka kwintliziyo kulabo abane-acid reflux. Ngezifo ezinzima, ingasetyenziselwa yodwa. Kwabo banokugqithisa kakhulu, kubonakala ukuba iGavison ingaba yongezelelo eluncedo kubantu abanempendulo enganeleyo kwiproton pump inhibitors . Ukongeza kwimiqondiso yokunciphisa kunye neenombolo zee-epluode ze-reflux, i-Gaviscon ibonakala iyancipha i-postprandial (emva kokuba idle) amanqanaba e-asidi kwipopu njengoko ilinganiswe ngeprogram ye-pH.

Izithako kunye neenkcukacha zeMveliso

Iibhulethi Zamandla onke rhoqo (kwipilisi nganye)

Iipilisi ezongezelelweyo zamandla (kwi-tablet nganye)

IsiXhosa esisisigxina (rhoqo kwipunipoon)

I-Power Strength Extra (in nganye ithispoon)

Ukusetyenziswa

I-Gaviscon iza njengepilisi ehlaziyiweyo kunye nolwelo oluthatha umlomo. Ukuze amayeza asebenze ngokufanelekileyo kufuneka uhlaziye iipilisi ngokufanelekileyo kwaye akufanele ugxinise. Phuza ingilazi yamanzi emva kokuba uthathe amacwecwe. Gubungela kakuhle umbane phambi komsebenzi ngamnye ukudibanisa iyeza ngokulinganayo. Umbane unokudibaniswa namanzi okanye ubisi.

Landela iikhompyutheni kwileyibhile yephayibhile okanye kwileyibrari yakho yesigcawu ngokucophelela, kwaye ucele ugqirha wakho okanye ukhemistri ukuba achaze nayiphi na into ongaziqondiyo. Thatha i-aluminium hydroxide kunye ne-anti-magnesium antacids ngokuchanekileyo. Musa ukuthatha ngaphezulu okanye ngaphantsi okanye uthathe ixesha elide kunokuba umiselwe ugqirha wakho. Musa ukuthatha i-antacids ngaphezu kweyure ukuya kwiiveki ezimbini ngaphandle kokuba kumiselwe ugqirha wakho.

Ukuqapha okuKhethekileyo

Thatha la maqhinga okufumana iziphumo eziphambili kwaye unciphise iziphumo zecala:

Imiphumela

Imiphumo emibi evela eGaviscon ayiqhelekanga. Enyanisweni, uvavanyo lwango-2016 olujongene nomphumo weGaviscon ukuguquka kwamanzi akufumani mmahluko kwimiphumo emibi phakathi kwabasebenzisa i-Gaviscon kunye nabo bathatha indawo ye-placebo. Sekunjalo, kukho iziphumo ezinokuthi zenzeke. Tshela ugqirha wakho ukuba nayiphi na le mpawu iyanzima okanye ungahambi:

Imithombo:

> Reimer C, uLødrup AB, Smith G, Wilkinson J, Bytzer P. Uvavanyo lweNzululwazi oluLungisiweyo: i-Alginate (i-Gaviscon Advance) kunye ne-Placebo njenge-Ad-on Onrapy kwi-Patients Reflux ngeempendulo ezinganelanga kwi-Daily Proton Pump Inhibitor. I-Pharmacology ne-Therapeutics ezidliwayo 43, akukho. 8 (2016): 899-909. i-doi: 10.1111 / apt.13567.

> Thomas E., Wade A., Crawford G., Jenner B., Levinson N., uWilkinson J. Randomized Trial Clinical Trial: Ukuncedwa kweMpawu eziPhakamileyo zeZondlo nge-Acid Pocket-Targeting Alginate-Antacid (i-Gaviscon Double Action) -Blind, i-Placebo-Controlled, iSifundo soPhando kwi-Gastro-oesophageal Reflux Disease. I-Pharmacology kunye neeTherapeutics . 2014. 39 (6): 595-602.

> Yuan YZ, Fang JY, Zou DW, Levinson N, Jenner B, Wilkinson J. Alginate-Antacid (i-Gaviscon Double Action) Amathebhulethi athengwayo Ukunciphisa ukukhanya kwe-Acophageal Acid Exhibure kwizilwanyana zaseTshayina ezinezifo ze-Gastroesophageal Reflux Diseases and Breast Symptoms s. I-Journal of Digestive Diseases . 2016; 17 (11): 725-734. i-doi: 10.1111 / 1751-2980.12406.